Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
B 19.72 -1.94% -0.39
ACAD closed down 1.94 percent on Wednesday, February 8, 2023, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Feb 27
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Multiple of Ten Bearish Other 0.00%
Overbought Stochastic Strength 0.00%
Gapped Down Weakness 0.00%
Pocket Pivot Bullish Swing Setup -1.94%
Multiple of Ten Bullish Other -1.94%
Overbought Stochastic Strength -1.94%
NR7 Range Contraction -0.65%
Narrow Range Bar Range Contraction -0.65%
Multiple of Ten Bearish Other -0.65%
Inside Day Range Contraction -0.65%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day about 10 hours ago
60 Minute Opening Range Breakdown about 14 hours ago
Down 1% about 14 hours ago
Gap Down Closed about 14 hours ago
Gap Down Partially Closed about 14 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

ACADIA Pharmaceuticals Inc. Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Medication Chemical Compounds Alzheimer's Disease Parkinson's Disease Schizophrenia Chronic Pain Neurological Disorders Central Nervous System Disorders Nervous System Disorders Glaucoma Urological Disorders Treatment Of Parkinson's Disease Treatment Of Chronic Pain Treatment Of Glaucoma Treatment Of Alzheimer's Disease Treatment Of Schizophrenia Psychosis Muscarinic Agonist

Is ACAD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 28.055
52 Week Low 12.24
Average Volume 1,133,357
200-Day Moving Average 16.49
50-Day Moving Average 16.94
20-Day Moving Average 18.88
10-Day Moving Average 19.31
Average True Range 0.59
RSI 65.87
ADX 47.36
+DI 32.77
-DI 7.99
Chandelier Exit (Long, 3 ATRs) 18.41
Chandelier Exit (Short, 3 ATRs) 18.46
Upper Bollinger Bands 20.39
Lower Bollinger Band 17.37
Percent B (%b) 0.78
BandWidth 15.99
MACD Line 0.82
MACD Signal Line 0.80
MACD Histogram 0.0237
Fundamentals Value
Market Cap 3.14 Billion
Num Shares 159 Million
EPS -1.97
Price-to-Earnings (P/E) Ratio -10.03
Price-to-Sales 19.85
Price-to-Book 12.93
PEG Ratio -0.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.34
Resistance 3 (R3) 20.40 20.27 20.23
Resistance 2 (R2) 20.27 20.11 20.23 20.20
Resistance 1 (R1) 19.99 20.01 19.93 19.93 20.16
Pivot Point 19.86 19.86 19.82 19.82 19.86
Support 1 (S1) 19.58 19.70 19.52 19.52 19.28
Support 2 (S2) 19.45 19.60 19.41 19.24
Support 3 (S3) 19.17 19.45 19.21
Support 4 (S4) 19.11